Author Archive

BPC July 26 updates: REPH jumps 50% after hours on Phase 3 data. TKAI share price collapses on Phase 3 fail + updates for ADXS HALO RDHL SGEN TNXP

Jul 27, 2016 No Comments by

Updates to the Company Pipeline Database for July 26, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ADXS 8.03 Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 second dose-escalation cohort completed July 2016 HALO 9.52 Eribulin In Combination With […]

Daily News Read more

BPC July 25 updates: MSTX data delay till September. OCUL issued CRL. TBRA Phase 2b NASH trial fail + updates for ACRS ALDR ALNY BLPH CANF EIGR GNVC HALO ONCE

Jul 26, 2016 No Comments by

Updates to the Company Pipeline Database for July 25, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACRS 19.72 A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data due 3Q 2016 ACRS 19.72 A-101 Seborrheic keratosis (SK) Phase 3 Phase 3 data due 4Q 2016 ALDR 28.72 ALD403 Chronic […]

Daily News Read more

BPC July 21 updates: PBYI submits Neratinib NDA filing + MATN commences Phase 2 ovarian cancer enrolment

Jul 22, 2016 No Comments by

Updates to the Company Pipeline Database for July 21, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary MATN 0.72 CA4P with Pazopanib Ovarian cancer Phase 2 Phase 2 enrolment commenced July 2016 PBYI 34.52 PB272 ExteNET trial Extended adjuvant HER2-positive early stage breast cancer NDA filing Announced NDA filing July […]

Daily News Read more

BPC July 20 updates: RLYP to be acquired by Galenica for $32 per share

Jul 21, 2016 No Comments

Updates to the Company Pipeline Database for July 20, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary RLYP 20.10 Veltassa Hyperkalemia Approved Approved October 21 2015. To be acquired by Galenica Group (SIX:GALN) for $32 per share – announced July 21 2016

Read more

BPC July 19 updates: After hours – PGNX up 35% on FDA Approval while ZFGN falls 40% on decision to suspend Beloranib development + ABUS update

Jul 20, 2016 No Comments

Updates to the Company Pipeline Database for July 19, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ABUS 4.07 TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study PGNX 4.94 Oral RELISTOR Chronic pain Approved Approved July 19 […]

Read more

BPC July 18 updates: EVOK dives 70% on failed Phase 3 trial + updates for AGLE CYNA EIGR

Jul 19, 2016 No Comments

Updates to the Company Pipeline Database for July 18, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AGLE 4.48 AEB1102 Arginase I deficiency Phase 1 Phase 1 to initated 1H 2016. Top-line data due 1H 2017 AGLE 4.48 AEB1102 Hyperargininaemia and Hematological Malignancies Phase 1 Phase 1 initation announced July […]

Read more

BPC July 15 updates: ELTP issued CRL. SGYP Phase 3 IBS-C data delayed till 4Q.

Jul 15, 2016 No Comments

Updates to the Company Pipeline Database for July 15, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ELTP 0.31 SequestOx Moderate to severe pain CRL CRL issued July 15 2016 SGYP 3.61 Plecanatide Constipation-predominant irritable bowel syndrome (IBS-C). Phase 3 Phase 3 data due 4Q 2016

Read more

BPC July 14 updates: BCLI Phase 2 ALS data due July 18. RARE releases Phase 3 data + RVNC Phase 3 RT002 trial to be initiated 2H 2016

Jul 15, 2016 No Comments

Updates to the Company Pipeline Database for July 14, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary RARE 49.54 rhGUS Mucopolysaccharidosis 7 (MPS 7) Phase 3 Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. RVNC 13.84 RT002 Moderate to severe glabellar (frown) lines Phase 2 Phase 3 […]

Read more

BPC July 13 updates: RARE Phase 3 data due TODAY. MNOV interim Phase 2b MS analysis due 4Q + LOXO update

Jul 14, 2016 No Comments

Updates to the Company Pipeline Database for July 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary LOXO 26.57 LOXO-101 Solid tumors that harbor a TRK fusion. Phase 2 Phase 2 basket trial initiated October 2015. Enrolment update due 2H 2016 MNOV 7.03 MN-166 Progressive multiple sclerosis (progressive MS) Phase […]

Read more

BPC July 12 updates: SAGE hits Phase 2 endpoint. JUNO clinical hold lifted + updates for ITEK AVIR

Jul 13, 2016 2 Comments

Updates to the Company Pipeline Database for July 12, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AVIR 1.25 BTA585 Respiratory syncytial virus (RSV) infections Phase 2a Phase 2a enrolment resumed July 2016. Trial to be completed by end of 2016 ITEK 8.51 Trabodenoson and latanoprost Glaucoma Phase 2 Phase […]

Read more

BPC July 11 updates: CYTR tumbles on poor data. SCMP discontinues Cobiprostone program + updates for ACST CHRS CLDX CYTR MYOK

Jul 11, 2016 No Comments

Updates to the Company Pipeline Database for July 11, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACST 1.33 CaPre (TRIFECTA trial) Hypertriglyceridemia Phase 2 Phase 3 planned CHRS 21.93 CHS-1701 Pegfilgrastim biosimilar BLA filing BLA to filed 3Q 2016 CLDX 4.57 CDX-014 Renal cell carcinoma (RCC) – cancer Phase […]

Read more